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tions. Relative effectiveness for glycaemic control (HbA1c) and
hypoglycaemia was determined from pivotal clinical trials.
RESULTS: Pooled analysis of pre-registration studies showed no
difference in HbA1c between glargine-treated patients and NPH
but did show a 28% risk reduction in severe hypoglycaemic
episodes and a 22% risk reduction in nocturnal hypoglycaemic
episodes compared to NPH. Over 40 years, treatment with NPH
resulted in 42,518 additional severe hypoglycaemic events and
662,698 additional nocturnal hypoglycaemic events compared to
insulin glargine. The discounted incremental cost effectiveness
ratio (ICER) was £12,302 per quality adjusted life year (QALY)
gained. Sensitivity analyses showed these ﬁndings were robust.
CONCLUSIONS: For any given degree of glycaemia, there was
reduced likelihood of severe and nocturnal hypoglycaemia with
glargine. Insulin glargine is cost-effective when used as basal
insulin for the treatment of people with Type 1 Diabetes. The
ICER is well within accepted thresholds for cost-effective treat-
ments in the UK.
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OBJECTIVES: The 2-year RESULT study demonstrated that
rosiglitazone (RSG) + sulphonylurea (SU) induced a sustained
increase in beta-cell function (BCF) (56%, p < 0.0001) compared
to no change with SU alone (6% p = 0.41). This study explores
the impact of modelling improved BCF on predicted lifetime
health outcomes and health care expenditure in Spain.
METHODS: DiDACT, a peer-reviewed published long-term
model of T2DM, was used to project the natural lifetime pro-
gression of T2DM for 1000 Spanish patients with characteris-
tics matched to those in the RESULT study (73% male, mean
age 68.2 years, mean BMI 30 kg/m2). Following failure to main-
tain glycaemic target (HbA1C ≥ 7.5%) with intermediate dose
of SU, up-titration of SU therapy was compared to RSG + SU
combination. Future costs and outcomes were discounted at 5%
per year. The original calibration of RSG in DiDACT was based
primarily on insulin sensitization. Improved BCF can be repre-
sented by using an additive, multiplicative or combined
approach. The additive representation assumes a one-off change
independent of existing BCF. The multiplicative representation
assumes the impact is proportionate to current BCF. RESULTS:
The ﬁndings demonstrate that both multiplicative and additive
approaches to representing RSG’s effect on BCF result in reduced
lifetime costs and increased Quality Adjusted Life-Years
(QALYs) compared with the previous calibration, with cost-
effectiveness ratios falling well below both established thresholds
and previous estimates. CONCLUSIONS: Each modelling
method of the impact of improved BCF in the management of
T2DM indicated that RSG is more cost-effective than previously
estimated. The impact of RSG on BCF may be conﬁrmed in next
forthcoming long-term studies.
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OBJECTIVES: To examine if close control of blood glucose
levels in patients with type 2 diabetes treated with diet restric-
tions or oral medication has an economic beneﬁt. METHODS:
A decision analytic model with a time horizon of eight years has
been developed. Costs are assessed from the perspective of the
Swiss health care system. Data on the efﬁcacy of SMBG come
from the large observational ROSSO study conducted in
Germany. The economic endpoint is the impact of blood glucose
monitoring on direct medical costs, taking into account reduced
costs due to ﬁve major diabetes-related complications (myocar-
dial infarction (MI), stroke, haemodialysis due to renal failure,
blindness, and foot amputation), and assuming no difference in
all other direct medical costs of diabetes. The clinical endpoint
is quality adjusted life years (QALYs) gained. RESULTS: Self-
monitoring of blood glucose induces a cost saving of CHF1062
over eight years due to a reduction in the number of diabetes-
related complications. This hints at an annual budget saving in
diabetes related complications of CHF21 Mio. per year, based
on an estimate of 160000 non-insulin treated type 2 diabetes
patients in Switzerland. In addition, the quality of life is
improved for patients performing SMBG. A critical parameter is
the number of test strips used. A sensitivity analysis shows that
with a weekly consumption of more than 5.25 strips per patient,
SMBG is no longer a dominant strategy. No related, evidence-
based guidelines are currently available. CONCLUSIONS: The
potential economic beneﬁt of self-monitoring of blood glucose
among non insulin dependent type 2 diabetes patients seems to
be substantial in Switzerland, due to a reduction in long-term
diabetes complications.
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OBJECTIVES: To evaluate lifetime clinical and economic out-
comes in the Swedish setting for patients with type 1 diabetes
treated with either insulin aspart (IAsp) or human soluble insulin
(HSI) as mealtime insulin, based on a multinational clinical trial.
METHODS: A validated diabetes model was used to project
long-term cumulative incidence of complications, life expectancy
(LE), quality-adjusted life expectancy (QALE) and lifetime costs
for IAsp versus HSI. Markov modeling techniques were used to
describe incidence and progression of complications (eye, renal
and cardiovascular disease, and peripheral neuropathy), and
Monte Carlo simulation accounted for uncertainty. Probabilities
of complications and HbA1c-dependent adjustments were
derived from landmark clinical and epidemiological studies.
Cohort deﬁnition and intervention effects were taken from a 30-
month multicenter, multinational, open-labeled phase III exten-
sion trial in patients with type 1 diabetes. Costs were retrieved
from published sources and expressed in 2005 Swedish Kronor
(SEK) from a societal perspective (human capital approach). LE,
QALE and total costs were projected over a 50-year time horizon
and discounted at 3% per annum. RESULTS: IAsp was associ-
ated with an increase in LE of 0.13 years (16.38 ± 0.17 versus
16.26 ± 0.17) and in QALE of 0.14 quality-adjusted life years
(QALYs) (10.86 ± 0.11 versus 10.72 ± 0.11) compared to HSI.
The cumulative incidence of most diabetes-related complications
was estimated to be lower for IAsp versus HSI. Long-term direct
costs were slightly higher with IAsp than with HSI (SEK 568,532
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± 13,682 versus 567,920 ± 15,127), leading to an incremental
cost-effectiveness ratio of SEK 4373 per QALY gained for IAsp
versus HSI. From a societal perspective, IAsp was life and cost
saving (dominant) compared to HSI, assuming that workplace
productivity improved with diabetes-related complications
avoided. CONCLUSIONS: Over patient lifetimes, IAsp was pro-
jected to improve LE and QALE and reduce the cumulative inci-
dence of diabetes-related complications, with cost savings from
a societal perspective in Sweden, compared to HSI.
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OBJECTIVES: To estimate the long-term clinical and economic
outcomes associated with repaglinide or nateglinide therapy,
both in combination with metformin, in patients with type 2 dia-
betes inadequately controlled with sulfonylurea or metformin
monotherapy, or with low dose glybenclamide plus metformin
in the Swedish setting. Based on the results of a recent 16-week
clinical trial. METHODS: A published and validated, interactive
computer model was adapted to project life expectancy (LE),
quality-adjusted life expectancy (QALE), cumulative incidence of
complications and costs in the Swedish setting. The model com-
prises a series of Markov sub-models that simulate the long-term
incidence and progression of diabetes-related complications
based on published data. Baseline cohort characteristics (mean
age 55.8 years, duration of diabetes 7 years, HbA1c 8.4%, BMI
33 kg.m-2) and intervention effects were derived from the clini-
cal trial. Costs were accounted from a societal perspective (treat-
ment, complication and lost-productivity costs) and expressed in
year 2005 Swedish Kronor (SEK) values. Clinical and cost out-
comes were projected over a lifetime horizon and discounted at
3% per annum. RESULTS: Repaglinide + metformin was asso-
ciated with an increase in LE of 0.21 years (9.82 ± 0.18 versus
9.61 ± 0.17) and in QALE of 0.17 quality-adjusted life years
(6.34 ± 0.12 versus 6.17 ± 0.11) compared to nateglinide + met-
formin. There was a reduced cumulative incidence of diabetes-
related complications associated with repaglinide + metformin
treatment, most notably for retinopathy and nephropathy, com-
pared to nateglinide + meformin. Lifetime costs were lower for
repaglinide + metformin compared to nateglinide + metformin
from both a third party payer (SEK 337,897 ± 11,471 versus
SEK 380,867 ± 13,226) and societal perspective (SEK 629,525
± 22,446 versus SEK 647,635 ± 21,191). CONCLUSIONS:
Treatment with repaglinide + metformin was projected to be
associated with increased time free of diabetes-related complica-
tions and dominant (cost and life saving) from a societal per-
spective, compared to nateglinide + metformin, in the Swedish
setting.
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OBJECTIVES: To project the long-term clinical and economic
outcomes associated with continuous subcutaneous insulin 
infusion (CSII) compared with multiple daily injection (MDI) 
in patients with type 1 diabetes in Sweden and Norway.
METHODS: A previously published and validated computer
simulation model of type 1 diabetes was adapted to project life
expectancy (LE), quality-adjusted life expectancy (QALE) and
costs in Norwegian and Swedish settings. Effects associated with
CSII and MDI delivery systems and baseline simulated cohort
characteristics (mean age 26 years, duration of diabetes 12 years,
54% male, mean HbA1c 8.68%) were taken from a recent meta-
analysis. Direct medical costs and indirect costs (human capital
approach) were accounted in year 2005 values. Clinical and cost
outcomes were projected over a lifetime horizon and discounted
at a rate of 3% per annum. RESULTS: CSII treatment was 
associated with increased LE versus MDI in the Norwegian 
and Swedish settings (0.95 and 1.03 years, respectively) and
increased QALE (0.98 and 1.03 quality-adjusted life years
(QALYs), respectively). The cumulative incidence of diabetes-
related complications, particularly nephropathy and retinopathy
complications was also lower in the CSII treatment arm com-
pared to MDI. Mean lifetime costs were greater for CSII treat-
ment compared to MDI in the Norwegian setting (NOK
3,505,368 ± 77,645 versus 3,480,974 ± 76,698), which pro-
duced an incremental cost-effectiveness ratio (ICER) of NOK
24,837 (∼€3200) per QALY gained for CSII versus MDI. In the
Swedish setting CSII was also associated with higher lifetime
costs compared to MDI (SEK 3,026,056 ± 58,873 vs 2,965,366
± 60,025) which led to an ICER of SEK 58,830 (∼€6300) per
QALY gained for CSII versus MDI. CONCLUSIONS: CSII was
associated with increased LE and QALE and reduced incidence
of diabetes-related complications compared to MDI. CSII repre-
sents good value for money in the Norwegian and Swedish
setting from a societal perspective by generally accepted 
standards.
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OBJECTIVES: The purpose of this study was to evaluate the rel-
ative cost effectiveness (cost utility) of insulin glargine versus
NPH insulin in the UK for the treatment of people with type 2
diabetes mellitus (T2DM) using pooled data from the Phase III
clinical trials programme. METHODS: This was a health eco-
nomic evaluation using a stochastic simulation model. Transition
probabilities for progression to diabetes-related complications
for the model were derived mainly from the UKPDS (UK
Prospective Diabetes Study) risk equations. Costs were derived
from published estimates and local data. The maximum time
horizon was 40 years to ensure effective modelling of diabetes
